Top Featured Companies Dominating the Bell’s Palsy Treatment Landscape
- Astellas Pharma Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- tVns Technologies Gmbh
- Novartis AG
- Sanofi-Aventis Groupe
- Abbott Laboraties
- Merck & Co., Inc.
- Siemens Healthcare GmbH.
- Pfizer Inc.
- Eli Lilly and Company.
- BioControl Medical.
Browse Key Market Insights with Data Illustration:
In the News
21 July, 2020: Surgeons at UT Southwestern have developed a cutting-edge technique for Bell’s Palsy patients, enabling effective eye closure and corneal protection. Detailed in a 2020 journal article, the procedure involves a sophisticated approach that reinnervates eye muscles, ensuring faster and more complete closure. It’s most beneficial for patients with paralysis for under 18 months. The research conducted by UT Southwestern team has demonstrated that patients undergoing this procedure experience faster and more complete eye closure, leading to enhanced protection of the cornea. This innovation represents a significant advancement in Bell’s palsy treatment, underscoring UT Southwestern’s commitment to pioneering research and clinical excellence in reconstructive surgery.
April 27, 2023: Research in JAMA Otolaryngology – Head and Neck surgery compared Bell’s palsy incidence in Cvoid-19 vaccine recipients to unvaccinated or placebo groups. While incidence was higher among vaccinated individuals in randomized trails, no association was found in observational studies. Additionally, bell’s palsy was more common during CVOID-19infecion than after vaccination, with significant increase in risk compared to SARS-CoV-2 vaccines. Furthermore, more research is required to verify the results so far and also understand why some individuals develop Bell’s palsy after vaccination.
